Почетна › Беркитов лимфом › Minesota
Kliničke studije za Беркитов лимфом u državi Minesota
10 studija za Беркитов лимфом traži učesnike na lokacijama u državi Minesota.
Gradovi u državi Minesota
Zvanični tekst studije (na engleskom)
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
Тражи се учесникФаза 2
Узраст од 1 до 30 · Оба пола · Ажурирано 12. 11. 2026. · NCT04546399Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Essentia Health Cancer Center, Duluth
- Abbott-Northwestern Hospital, Minneapolis
- Mayo Clinic in Rochester, Rochester
Тражи се учесникФаза 3
Узраст од 18 до 39 · Оба пола · Ажурирано 3. 11. 2026. · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- University of Minnesota/Masonic Cancer Center, Minneapolis
Тражи се учесникФаза 2
365 Days · Оба пола · Ажурирано 27. 10. 2026. · NCT06317662A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
Тражи се учесникФаза 2
366 Days – 46 Years · Оба пола · Ажурирано 27. 10. 2026. · NCT06124157Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
Тражи се учесникФаза 1/2
Узраст од 13 до 90 · Оба пола · Ажурирано 26. 10. 2026. · NCT06533579Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Minnesota, Minneapolis
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 8. 9. 2026. · NCT03666000Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
Тражи се учесникФаза 3
365 Days – 25 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Hospitals and Clinics of Minnesota, Minneapolis
Тражи се учесникФаза 2
Узраст од 7 до 25 · Оба пола · Ажурирано 19. 8. 2026. · NCT05082519Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
Тражи се учесникФаза 2
До 75 година · Оба пола · Ажурирано 6. 7. 2026. · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
Тражи се учесникФаза 2
До 60 година · Оба пола · Ажурирано 25. 6. 2026. · NCT03314974Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.